학술논문
PMS19 - Cost Per Response of Certolizumab Pegol Versus Adalimumab Among Biologic-Naïve Patients With Moderate or Severe Rheumatoid Arthritis from the US Payer Perspective
Document Type
Abstract
Author
Source
In Value in Health May 2018 21 Supplement 1:S194-S194
Subject
Language
ISSN
1098-3015